Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00384436 · ClinicalTrials.gov registry record · Phase 4
Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients
A Phase 4 study of Major Depressive Disorder, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 4
- Development phase
- 580
- Enrollment target
- 1
- Study location
NCT00384436: Completed Phase 4 study of Major Depressive Disorder, sponsored by Forest Laboratories.
NCT00384436 is a Phase 4 study of Major Depressive Disorder that has completed, run by Forest Laboratories. The registered enrollment target is 580 participants, above the 375-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (55% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00384436, a Phase 4 study of Major Depressive Disorder, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 580 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and efficacy of escitalopram to an active comparator in severely depressed patients
Conditions Studied
Interventions
- DRUG escitalopram
Study Locations (1)
Missouri
- For information regarding investigative sites, contact Forest Professional Affairs - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 580 participants |
| Start Date | 2006-10 |
| Phase | Phase 4 |
What the finished NCT00384436 record still lists
NCT00384436 is an interventional study that assigns participants to a tested intervention. The registered 580 participants enrollment target is mid-sized for trials with a published cap, above the 375-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (55% higher).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which escitalopram is the first listed.
NCT00384436 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT00384436 about?
NCT00384436 is a clinical study titled "Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients". The purpose of this study is to evaluate the safety and efficacy of escitalopram to an active comparator in severely depressed patients
What is the current status of trial NCT00384436?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 580 participants. The study started on 2006-10.
What conditions does trial NCT00384436 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT00384436?
The interventions under investigation include: escitalopram (DRUG).
Who is sponsoring clinical trial NCT00384436?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00384436 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00384436's enrollment target sits among peer trials
580 24th of 282 higher than 259 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
RECRUITING · Phase 4
-
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
RECRUITING · Phase 4
-
Neural Circuit Effects of Ketamine in Depression
RECRUITING · Phase 4
-
Aβ Dynamics in LLMD
RECRUITING · Phase 4
-
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04575935 · 580 participants · Phase 3
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- NCT05143177 · 580 participants · Phase 2
A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
- NCT05696353 · 580 participants · Phase 3
Teen Driving Translation Study (NIH)
- NCT06578104 · 580 participants
PULSED AF Post-Approval Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia